Board summary
Key figures
42,940
Registered population
54.8% aged 18–64
27.6%
Aged 65+
ICB 19.9% · England 17.9%
4.5%
Ethnic minority (non-White)
1.9% Asian · England 9.6%
21.5%
In IMD quintile 1
ICB 17.1% · England 21.0%
~8,677
Core20 residents (est.)
Resident basis; registered basis ~9,227 · see page 3
9,527
Hypertension register
+8.87% in 3 yrs · England +5.60%
551
SMI register
26.2% of Canterbury's
1,233
COPD register
Reviews +10.27% in 3 yrs
Forecast to 2030
12,481
Hypertension patients, 2030
+2,954 on today
71.2%
QRISK ≥20% on statins, 2030
+3.67pp over 3 yrs
7.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review scale gap and smoke recording lag.
Annual asthma reviews reached 64.8% (England 65.7%), leaving a 1,135-patient scale gap alongside 61.4% paediatric second-hand smoke recording (England 78.8%), which may reflect recall.
Infant and pre-school vaccinations trail 95.0% target.
In Q1 2025/26, 12-month 6-in-1 coverage was 84.7% (10.3 pp below the 95.0% target; England 91.0%) and age-5 MMR2 was 89.7% across small cohorts.
Population, age and ethnicity
With 27.6% aged 65+, an older profile may heighten chronic disease demand
Herne Bay PCN serves 42,940 registered patients across two practices, with 27.6% aged 65+ (11,841 patients), above Canterbury (18.4%), NHS Kent and Medway ICB (19.9%) and England (17.9%). The 65+ share is 29.8% at The Heron Medical Practice and 26.0% at Park Surgery. Patients aged 18-64 comprise 54.8% (Canterbury 62.9%, ICB 59.5%, England 62.7%); aged 0-17 represent 17.6% (Canterbury 18.7%, ICB 20.7%, England 19.6%). Census usual residents are 95.5% White (Canterbury 89.2%, ICB 88.6%, England 81.1%), not registered patients. Projected 2030 list growth is 8.8% (Canterbury 7.0%, ICB 6.0%, England 2.3%), under unverified methodology.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Canterbury local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Canterbury LA) | 1,577 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Canterbury LA) | 682 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Canterbury LA) | 18.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 21.5% of patients, concentrating highest in Park Surgery
Across the PCN, 21.5% of registered patients live in Core20 areas, above Canterbury (19.3%), NHS Kent and Medway ICB (17.1%) and England (21.0%), despite an average IMD decile of 5.3. Park Surgery holds both the higher Core20 concentration (22.2%; 5,589 estimated patients) and larger list (25,143), while The Heron Medical Practice accounts for 20.4% (3,638 estimated patients; list 17,797). Resident estimates in national deciles 1 and 2 total 8,677. Targeted proactive outreach will need weighting toward Park Surgery while maintaining cross-site coverage.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
551
SMI register
1.30% recorded prevalence
371
Learning disability register
0.88% recorded prevalence
30
Care homes, 895 beds
In the PCN catchment
9.3%
Provide unpaid care
Canterbury, Census 2021
The PCN records 371 learning disability patients (0.9% prevalence vs Canterbury 0.6%, NHS Kent and Medway ICB 0.6%, England 0.6%) and 551 severe mental illness patients. Catchment facilities cover 30 care homes (895 beds). Canterbury borough figures show 29 rough sleepers and a ceiling of 3,993 unpaid carers, neither verified at PCN level.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.3%. Blood pressure checks reached 83.5% (England 83.4%), but BMI recording trailed at 79.8% (England 82.1%) and alcohol recording at 77.9% (England 81.8%), leaving cardiometabolic risks unassessed for some patients.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,527
Hypertension register
+8.87%
Register growth, 3 yrs
Canterbury +3.48% · England +5.60%
+1.57pp
BP control, under 80
≤140/90 · +0.55pp aged 80+
+2,954
More patients by 2030
Forecast 12,481 (26.70%)
Hypertension case-finding and control
Recorded hypertension prevalence is 22.5% (9,527 patients), well above Canterbury (15.6%), NHS Kent and Medway ICB (16.2%) and England (15.2%), consistent with an older population where 27.6% are aged 65+ (England 17.9%). While 70.6% of patients are treated to target (England 70.3%), three-year improvement in blood pressure recording rose +1.9% (England +3.6%), and patients with a recent blood pressure reading reached 88.4% (England 90.0%). At practice level, recorded readings reached 86.1% at The Heron Medical Practice and 90.3% at Park Surgery. With high recorded prevalence but blood pressure check progress trailing England, prioritising blood pressure recall audits at The Heron Medical Practice offers the greatest opportunity to close review gaps.
Lipids and statins
Statin treatment for diabetes without cardiovascular disease is 70.5% (England 73.2%), and for diabetes with cardiovascular history is 82.4% (England 84.4%). Among patients with QRISK ≥ 20%, 63.1% receive lipid-lowering therapy (England 63.6%). Lower statin coverage in diabetes than England suggests systematic medication review could improve cardiovascular prevention.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 92,433 | £2.20 | £1.90 | £1.86 | £203,353 |
| Cardiovascular (all), 2025 | 125,353 | £4.60 | £3.57 | £3.33 | £576,624 |
In 2026, the PCN prescribed 92,433 lipid-regulating drug items at £2.20 per item, above NHS Kent and Medway ICB (£1.90) and England (£1.86), representing £31,427 more than at England's unit cost. Higher unit costs relative to England indicate an opportunity to review lipid-regulating drug choices and formulary alignment.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.30%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+5.22%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.9% (1,233 patients), with 84.9% reviewed in 12 months (England 76.4%), rising +10.3% over three years (England +2.8%). Conversely, asthma prevalence is 8.0% (3,220 patients), but 12-month reviews reached 64.8% (England 65.7%), leaving an estimated scale gap of 1,135 unreviewed patients. Second-hand smoke status was recorded for only 61.4% of asthma patients aged 6-19 (England 78.8%), while asthma prescribing reached 2,165 items per 1,000 aged 5-19 (England 1,488). Prioritising paediatric asthma reviews could improve preventative management.
Cancer register and children's immunisation
Cancer prevalence is 6.1% (2,563 patients; England 3.8%). In Q1 2025/26, 12-month 6-in-1 immunisation was 84.7%, below the 95.0% target by 10.3 pp and behind England (91.0%), though 24-month completion reached 95.4%. At age 5, MMR dose 2 was 89.7% (5.3 pp below target), trailing dose 1 (95.9%) by 6.2 pp. These shortfalls suggest timely scheduling and recall require PCN-wide prioritisation.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of cancers with a known stage across NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (4,661 of 8,384), compared to 55.3% in England and below the 75.0% national ambition by 2028. Reaching 75.0% requires 1,627 extra early-stage cases across the ICB; known-stage cancers represented 63.6% (England 67.0%). These ICB figures reflect wider system pathways, not PCN performance. At PCN level, cervical screening coverage in women aged 25 to 49 is 68.5%, falling 0.9% from 2023 to 2025 (Canterbury +3.3%, England -1.0%). The 0.9% drop may indicate access barriers, which an appointment audit would test.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), East Kent Hospitals University NHS Foundation Trust achieved 70.0% on the 62-day cancer standard (standard 85.0%), below NHS Kent and Medway Integrated Care Board (75.9%) and England (71.2%). On the 28-day faster diagnosis standard, East Kent reached 71.3% (standard 75.0%, ICB 76.8%, England 79.3%). For diagnostics in July 2026, 48.4% of patients waited 6+ weeks at East Kent (England 23.1%), led by non-obstetric ultrasound at 63.0% (England 19.6%). These provider figures describe wider system activity, not PCN performance.
| Pathways within standard (%) | East Kent | Mid and South Essex | Medway | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.28 | 67.45 | 77.77 | 76.78 | 79.32 |
| 31-day treatment (96%) | 96.67 | 81.88 | 99.62 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 70.01 | 50.25 | 81.64 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Kent | Mid and South Essex | Medway | England |
|---|---|---|---|---|
| MRI | 47.58 | 23.35 | 0.68 | 21.40 |
| CT | 37.45 | 6.07 | 0.00 | 9.92 |
| Echocardiography | 14.17 | 65.05 | 36.62 | 28.48 |
| Colonoscopy | 9.58 | 64.09 | 1.88 | 30.83 |
| Gastroscopy | 22.16 | 59.76 | 3.32 | 29.02 |
| All 15 DM01 tests | 48.38 | 41.54 | 14.20 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026 (provisional), Kent recorded 210,170 community care contacts across 60,605 patients, with 138,250 contacts (65.8%) delivered to adults aged 65+. Across NHS Kent and Medway Integrated Care Board, 165,655 of 254,055 contacts involved patients aged 65+. These experimental figures describe wider system activity rather than PCN performance.
Practice variation and patient experience
Practice vaccination achievement varies by 49.7 pp while patient experience spans 17.8 pp
In 2025/26, both practices achieved 100.0% in QOF clinical domains (England 97.1%). Overall achievement reached 96.8% at The Heron Medical Practice and 91.2% at Park Surgery (England 92.5%). Vaccination and immunisation achievement diverged by 49.7 pp, spanning 22.4% at Park Surgery to 72.1% at The Heron Medical Practice (England 55.2%), which recall audits would test.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Park Surgery | 92 | 22.2 | 63.2% | 78.3% | 89.5% |
| Heron Medical | 119 | 20.4 | 56.3% | 71.8% | 71.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Ten of 25 three-year trends trailed England, led by heart failure reviews
Across 25 tracked measures, the PCN trailed England on 10 three-year trends. The widest lags were heart failure reviews, which fell 1.2% over 2023 to 2025 (England +8.7%, Canterbury -1.0%, NHS Kent and Medway ICB +8.5%; current rate 73.9% vs England 78.5%), psychosis alcohol recording, which rose +1.1 pp (England +5.4 pp; current rate 77.9%), and severe mental illness BMI recording, up +3.0 pp (England +5.1 pp; current rate 79.8%). Three-year strengths included COPD reviews (+10.3% vs England +2.8%), breast screening (+12.2% vs England +8.4%), and smoking cessation offers (+3.5 pp to 98.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Alcohol record (psychosis)
BMI record (SMI)
Hypertension treated to target
Hypertension BP reading
COPD reviews
Breast screening (53-70)
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Canterbury | Asset | PCN | Canterbury |
|---|---|---|---|---|---|
| Care homes (catchment) | 30 (895 beds) | n/a | Schools (catchment) | 27 | n/a |
| Children's centres | 3 | 8 | Places of worship | 23 | 103 |
| Libraries | n/a | 2 | Day centres (VCS) | n/a | 4 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 4 |
| Primary schools (LA maintained) | 5 | 19 | Primary academies | 4 | 13 |
| Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and smoke recall
Asthma 12-month reviews are 64.8% (England 65.7%), a scale gap of 1,135 on the 3,220 register; age 6-19 second-hand smoke recording is 61.4% (England 78.8%). For discussion, the PCN could run structured asthma recall using a single template with after-school slots and inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Childhood immunisation recall and catch-up
In Q1 2025/26, 12-month 6-in-1 coverage is 84.7% (85 children; England 91.0%), 10.3 pp below the 95.0% target; age-5 MMR2 is 89.7% (97 children), 5.3 pp below target. For discussion, practices could audit overdue infant and pre-school cohorts, adding prompt reminders and flexible catch-up slots. Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Heart failure and SMI review recall
Ten of 25 three-year changes trailed England: heart failure reviews fell 1.2% (England +8.7%; current 73.9% vs 78.5%) and SMI BMI checks rose +3.0 pp (England +5.1 pp; current 79.8% vs 82.1%). For discussion, the PCN could audit overdue heart failure and SMI reviews and run combined check clinics. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall and outreach (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | — | PCN |
| Telephony and access workflow review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and smoke recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Childhood immunisation recall and catch-up (p12) | 6-in-1 coverage at 12 months · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Heart failure and SMI review recall (p12) | Heart failure register · Severe mental illness register · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
